157 related articles for article (PubMed ID: 28426742)
21. Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype.
Flatmark K; Reed W; Halvorsen T; Sørensen O; Wiig JN; Larsen SG; Fodstad Ø; Giercksky KE
BMC Cancer; 2007 Jun; 7():116. PubMed ID: 17603904
[TBL] [Abstract][Full Text] [Related]
22. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases.
Nonaka D; Kusamura S; Baratti D; Casali P; Younan R; Deraco M
Histopathology; 2006 Oct; 49(4):381-7. PubMed ID: 16978201
[TBL] [Abstract][Full Text] [Related]
23. Targeting G-protein coupled receptor-related signaling pathway in a murine xenograft model of appendiceal pseudomyxoma peritonei.
Dilly AK; Honick BD; Lee YJ; Guo ZS; Zeh HJ; Bartlett DL; Choudry HA
Oncotarget; 2017 Dec; 8(63):106888-106900. PubMed ID: 29290997
[TBL] [Abstract][Full Text] [Related]
24. Targeting hypoxia-mediated mucin 2 production as a therapeutic strategy for mucinous tumors.
Dilly AK; Lee YJ; Zeh HJ; Guo ZS; Bartlett DL; Choudry HA
Transl Res; 2016 Mar; 169():19-30.e1. PubMed ID: 26589109
[TBL] [Abstract][Full Text] [Related]
25. Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines.
Roberts DL; O'Dwyer ST; Stern PL; Renehan AG
Oncotarget; 2015 May; 6(13):10786-800. PubMed ID: 25929336
[TBL] [Abstract][Full Text] [Related]
26. Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment.
Lohani K; Shetty S; Sharma P; Govindarajan V; Thomas P; Loggie B
Ann Surg Oncol; 2014 May; 21(5):1441-7. PubMed ID: 24046117
[TBL] [Abstract][Full Text] [Related]
27. Mucin as a therapeutic target in pseudomyxoma peritonei.
Choudry HA; O'Malley ME; Guo ZS; Zeh HJ; Bartlett DL
J Surg Oncol; 2012 Dec; 106(7):911-7. PubMed ID: 22585683
[TBL] [Abstract][Full Text] [Related]
28. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study.
Smeenk RM; van Velthuysen ML; Verwaal VJ; Zoetmulder FA
Eur J Surg Oncol; 2008 Feb; 34(2):196-201. PubMed ID: 17524597
[TBL] [Abstract][Full Text] [Related]
29. Mucinous Balls Tangled With Mesothelial Cells and MUC2-Positive Cancer Cells in the Ascites of Pseudomyxoma Peritonei.
Akashi S; Kuwabara H; Yasuda E; Akutagawa H; Takeshita A; Kurisu Y; Egashira Y; Hirose Y; Yuki M; Tsuda Y; Hayashi M
Diagn Cytopathol; 2016 Jul; 44(7):628-31. PubMed ID: 27079739
[TBL] [Abstract][Full Text] [Related]
30. Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review.
Lund-Andersen C; Torgunrud A; Fleten KG; Flatmark K
J Gastrointest Oncol; 2021 Apr; 12(Suppl 1):S191-S203. PubMed ID: 33968437
[TBL] [Abstract][Full Text] [Related]
31. Significance of epithelial cell clusters in pseudomyxoma peritonei.
Badyal RK; Khairwa A; Rajwanshi A; Nijhawan R; Radhika S; Gupta N; Dey P
Cytopathology; 2016 Dec; 27(6):418-426. PubMed ID: 27121698
[TBL] [Abstract][Full Text] [Related]
32. [Appendiceal mucoceles, pseudomyxoma peritonei and appendiceal mucinous neoplasms: update on the contribution of imaging to choice of surgical approach].
Gillion JF; Franco D; Chapuis O; Serpeau D; Convard JP; Jullès MC; Balaton A; Karkouche B; Capelle P; Parmentier T; Chollet JM; Thillois JM; Berthelot G
J Chir (Paris); 2009 Apr; 146(2):150-66. PubMed ID: 19552906
[TBL] [Abstract][Full Text] [Related]
33. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
34. Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP).
Pillai K; Akhter J; Mekkawy A; Chua TC; Morris DL
Int J Med Sci; 2017; 14(1):18-28. PubMed ID: 28138305
[No Abstract] [Full Text] [Related]
35. Pseudomyxoma peritonei. A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors.
Prayson RA; Hart WR; Petras RE
Am J Surg Pathol; 1994 Jun; 18(6):591-603. PubMed ID: 8179074
[TBL] [Abstract][Full Text] [Related]
36. TGF-beta regulates differentially the proliferation of fetal and adult human skin fibroblasts via the activation of PKA and the autocrine action of FGF-2.
Giannouli CC; Kletsas D
Cell Signal; 2006 Sep; 18(9):1417-29. PubMed ID: 16361081
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of single isolated cells with decreased E-cadherin expression in pseudomyxoma peritonei.
Koh YW; Jun SY; Kim KR
Pathol Int; 2014 Apr; 64(4):164-72. PubMed ID: 24750186
[TBL] [Abstract][Full Text] [Related]
38. Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.
Yan H; Pestieau SR; Shmookler BM; Sugarbaker PH
Mod Pathol; 2001 Mar; 14(3):164-71. PubMed ID: 11266521
[TBL] [Abstract][Full Text] [Related]
39. Gelatinous ascites: a cytohistologic study of pseudomyxoma peritonei in 67 patients.
Jackson SL; Fleming RA; Loggie BW; Geisinger KR
Mod Pathol; 2001 Jul; 14(7):664-71. PubMed ID: 11454998
[TBL] [Abstract][Full Text] [Related]
40. Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/β-catenin signaling pathway mutations.
Yuan W; Zhang Z; Dai B; Wei Q; Liu J; Liu Y; Liu Y; He L; Zhou D
Cancer; 2016 Jun; 122(11):1689-96. PubMed ID: 26998897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
